Hypofractionated Radiation Therapy (66 Gy in 22 Fractions at 3 Gy per Fraction) for Favorable-Risk Prostate Cancer: Long-term Outcomes

Patel, Nita; Faria, Sergio; Cury, Fabio; David, Marc; Duclos, Marie; Shenouda, George; Ruo, R.; Souhami, Luís

doi:10.1016/j.ijrobp.2013.02.010

Cited by 27 publications

(22 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The biochemical control and toxicity rates observed here can be considered encouraging, and comparable to the outcomes achieved using other fractionations and radiation techniques. The 5-year bNED for low-/intermediate-risk group (100%/94.6%) of the present study is comparable to the results of Patel et al 16 In their study, the Canadian group delivered 66 Gy in 22 fractions with 3D-CRT to 129 low-/intermediate-risk prostate cancer patients. With this fractionation, they achieved an actuarial bNED rate 97% at 5 years.…”

Section: Discussionsupporting

confidence: 87%

“…Other authors have graduate late toxicity with this approach. For instance, Patel et al 16 observed a rate of 27% and 32% for late grade ≥2 GI and GU toxicity, respectively, using 3D-CRT with 66 Gy/22 fractions (Table 3). In this Canadian series, Patel and colleagues did not use predefined constraints.…”

Section: Gastrointestinal Toxicitymentioning

confidence: 99%

“…In 2013, we compared this hypofractionated schedule with the conventional one (78 Gy in 39 fractions) in terms of acute toxicity. 16 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Treatment outcomes with hypofractionated high-dose radiation therapy for prostate cancer

Viani

Rossi

Suguikawa

et al. 2016

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Gastrointestinal Toxicitymentioning

confidence: 99%

See 1 more Smart Citation

Treatment outcomes with hypofractionated high-dose radiation therapy for prostate cancer

Viani

Rossi

Suguikawa

et al. 2016

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

“…At a median follow-up time of 90 months, the biochemical recurrence free rates at 5-and 8-year were 97 and 92%, respectively. The 8-year cancer specific and overall survival rates were 98 and 88%, respectively [8] (Fig. 2).…”

Section: Resultsmentioning

confidence: 96%

Hypofractionated radiation therapy for prostate cancer: The McGill University Health Center experience

Neto¹,

Souhami²,

Faria³

2015

Cancer/Radiothérapie

View full text Add to dashboard Cite

“…Radiobiological addition benefit allows hypofractionated RT decrease total treatment time which may be reflected in less expensive treatments. The conventional fractionation dose recommended for patients with low-risk prostate cancer is >75 Gy; with hypofractionation doses most used and most bibliographic support are recommended by Pollack et al (70.2 Gy/26 fractions of 2.7Gy/fraction) or of Kupelian et al [6] (70 Gy/28 fractions of 2.5 Gy/fraction) [3,5,7].…”

Section: Introductionmentioning

confidence: 99%

Untitled

2015

JCPCR

View full text Add to dashboard Cite

Objective: Get free interval biochemical failure and toxicity in patients treated with hypofractionated radiotherapy (HFRT, for its acronym in English, Hypofractionated Radiation Therapy) with IMRT (Intensity Modulated Radiation Therapy), administering 70 Gy in 28 fractions of 2.5 Gy. Methods:In May 2013 began in CDD Radioterapia Radioterapia Unit of Radiotherapy and Radiosurgery of Clinica Abreu, an hypofractionation program with IMRT as an alternative treatment for patients with localized prostate cancer favorable risk. The four selected patients had histologically confirmed prostate adenocarcinoma without prior radical treatment and categorized as low risk according to the criteria of D'Amico et al. For each patient a treatment plan is made based on Intensity Modulated Radiation Therapy (IMRT) more Image Guided Radiation Therapy (IGRT) with 18 MV photons from a linear accelerator CLINAC 21iX of the prestigious brand Varian®, administering doses of 70 Gy in 28 fractions of 2.5 Gy/day using an α/β 3, biologically equivalent to 76 Gy in 38 fractions of 2 Gy, under-Quadratic Linear Model. Patients were followed every 3 months for 18 months. The gastrointestinal and genitourinary toxicity (GI) (GU), was evaluated prospectively and classified according to the criteria of the RTOG (Radiation Therapy Oncology Group). As a definition of biochemical failure we use the RTOG criteria (definition Phoenix), considered the elevation of postradiotherapy PSA≥2 ng/mL above the nadir.Results: During follow-up of 18 months, all patients (100%) were free of biochemical failure. Only one patient presented grade 2 acute genitourinary toxicity, without having reported genitourinary or gastrointestinal late toxicity. This study is preliminary, with short follow and discreet patient population, however, is the first program and the first publication of hypofractionated treatment for prostate cancer radiotherapy in our country. Conclusion:Hypofractionated Radiotherapy (HFRT) is a valuable treatment option for patients with favorable risk prostate cancer, with an excellent result of biochemical control and low toxicity.

show abstract

Hypofractionated Radiation Therapy (66 Gy in 22 Fractions at 3 Gy per Fraction) for Favorable-Risk Prostate Cancer: Long-term Outcomes

Cited by 27 publications

References 23 publications

Treatment outcomes with hypofractionated high-dose radiation therapy for prostate cancer

Treatment outcomes with hypofractionated high-dose radiation therapy for prostate cancer

Hypofractionated radiation therapy for prostate cancer: The McGill University Health Center experience

Untitled

Contact Info

Product

Resources

About